Neuropathy, Alpha-Lipoic Acid and the Search for Something That Helps

Missing Script · Evidence review · October 2, 2026

A scan can look better while someone’s feet feel worse. That deserves more than a passing mention.

Neuropathy can mean burning, tingling, numbness, trouble buttoning a shirt or feeling unsteady on stairs. And when the usual options are limited, it makes sense that people go looking for something else. Alpha-lipoic acid. Vitamins. Glutamine. Acupuncture. A supplement somebody swears by.

I think we should take that search seriously. We should also be honest about what the trials actually tested.

First, which neuropathy? And which goal?

Preventing nerve injury while receiving oxaliplatin is different from treating painful neuropathy a year after paclitaxel. Diabetic neuropathy and a vitamin deficiency are different again. Pain relief, better balance and nerve recovery are also separate outcomes.

If we combine all of those into “good for nerves,” the label becomes more confident than the science.

This is a clinical evidence overview focused on adult chemotherapy neuropathy, with diabetic studies included where they explain the alpha-lipoic acid story. It covers the main supplement and integrative trials, including selected newer reports through October 2026. It is a narrative review, not an exhaustive systematic review of every neuropathy cause, botanical or laboratory experiment.

Alpha-lipoic acid: why it keeps coming up

Alpha-lipoic acid, or ALA, is an antioxidant involved in cellular metabolism. The idea is plausible. But plausibility is where a trial starts.

In SYDNEY 2, 181 people with diabetic neuropathy were randomized to oral ALA or placebo for five weeks. Symptoms improved more with ALA; higher doses caused more nausea, vomiting and vertigo. That is a short-term symptom result, not proof that damaged nerves were permanently restored.

The 2024 Cochrane review asked a longer-term question. Across three trials involving 816 adults, ALA probably had little or no effect on diabetic neuropathy symptoms at six months. The review did not establish improvements in quality of life, ulcers or amputations. Short studies and longer studies can give different answers.

The four-year NATHAN 1 trial did not meet its main composite nerve-function endpoint, although some secondary examination measures improved. That distinction matters when a study is described as “positive.”

Newer evidence has not made this simple. The 2026 OPTIMUM trial randomized 151 people with painful diabetic neuropathy to ALA, pregabalin or both for 12 weeks. Pregabalin alone met the study’s criterion for being no worse than the combination. The trial was open-label; exploratory subgroup findings need confirmation. A 2026 network meta-analysis reported benefits in some symptom and examination scores, but acknowledged substantial bias affecting initial rankings. Changes in those scores do not, by themselves, demonstrate structural nerve repair.

What about chemotherapy neuropathy?

A 2014 placebo-controlled prevention trial enrolled 243 people receiving platinum chemotherapy. ALA was given at 600 mg three times daily for 24 weeks. Only 70 completed the study. There was no significant improvement in neuropathy, pain or functional outcomes. The dropout problem weakens what we can conclude, but the study did not demonstrate benefit.

Then there is a smaller positive study we should not ignore. A 2022 breast cancer trial randomized 72 women and analyzed 64 receiving doxorubicin-based chemotherapy followed by paclitaxel. ALA 600 mg daily for six months improved neuropathy grading and questionnaire scores at later paclitaxel assessments. This is encouraging, but small, and it studied prevention during treatment—not reversal of longstanding neuropathy.

Studies combining ALA with ipidacrine, a prescription drug, have also reported favorable nerve measures. A combination trial cannot tell us what ALA contributed on its own.

My read: ALA deserves better trials. The existing data are not strong enough for me to call it dependable CIPN prevention, much less a cure. The doses above describe research; they are not a self-treatment plan.

Safety belongs here too. Digestive side effects are real, and rare cases of autoimmune hypoglycemia have been reported. Bring your glucose-lowering medicines and exact supplement label into the discussion. During cancer treatment, antioxidant use should be reviewed with the oncology team rather than assumed harmless.

The rest of the evidence, without the sales pitch

Acetyl-L-carnitine: the cautionary trial

In a placebo-controlled study of 409 evaluable women receiving taxanes for breast cancer, acetyl-L-carnitine did not help at 12 weeks and worsened neuropathy at 24 weeks. This is why “natural, so probably worth a try” is not enough. ASCO discourages its use for CIPN prevention.

Omega-3 and glutamine: interesting prevention signals

A small randomized omega-3 trial during paclitaxel reported less neuropathy. The result needs larger replication and does not establish that commercial fish-oil or algae-oil products treat established CIPN. Formulation matters.

An 86-person randomized glutamine study in metastatic colorectal cancer reported less oxaliplatin neuropathy. It lacked a placebo comparison. This is also a different clinical question from glutamine plus chemotherapy as a pancreatic cancer treatment strategy. Neither study should be used as a shortcut to answer the other.

Vitamins: fix a deficiency, question the megadose

Early vitamin E studies were positive, but a larger phase 3 trial with 189 evaluable patients found no reduction in clinically significant neuropathy. A placebo-controlled B-complex trial did not show benefit on its main neurologist-assessed outcome, despite a signal in patient-reported sensory symptoms.

That does not mean ignoring B12 deficiency. A one-year trial in 90 metformin-treated people with diabetes and low B12 levels reported improvements in several nerve and symptom measures with B12 replacement. That specific setting is different from adding vitamins when levels are adequate. Also, excess supplemental B6 can itself cause sensory neuropathy. Check the combined amount across “nerve support,” multivitamin and energy products.

Curcumin and NAC: newer findings worth following

A 2026 curcumin trial enrolled 70 adults with established platinum neuropathy; 65 completed four weeks. Sensory and total symptom scores improved compared with placebo, while motor and autonomic measures did not. The study was short and relied on questionnaires, not demonstrated nerve regeneration. Its formulation is not interchangeable with kitchen turmeric.

A separate 2025 trial in children with acute lymphoblastic leukemia reported less vincristine neuropathy with curcumin. That is another reason to investigate it, but pediatric leukemia, adult platinum chemotherapy and different formulations cannot be treated as one result.

N-acetylcysteine (NAC) has conflicting randomized results. A 2024 report found no meaningful prevention benefit in taxane-treated breast cancer patients. A 2025 paclitaxel study reported less neuropathy. Both deserve to be in the conversation. We need replication and treatment-specific safety data before turning this into routine advice.

Intravenous glutathione has been studied too, but the phase 3 N08CA trial did not support prevention during carboplatin/paclitaxel. An infusion trial also does not validate an oral antioxidant supplement.

Herbal mixtures and cannabinoids: read past the headline

Goshajinkigan is a Japanese multi-herb preparation. The GENIUS phase 3 oxaliplatin trial found more grade 2 or worse neuropathy with it. A later small paclitaxel trial reported favorable outcomes. Different chemotherapy, different design, different answer. The unfavorable study cannot be left out.

A 2025 CBD/THC trial randomized 46 people with established CIPN. Its primary analysis was negative; a secondary analysis suggested improvement in sensory symptoms, without a pain benefit. A topical CBD pilot was also negative. These are not grounds for a general promise that cannabis repairs nerves.

The 8% capsaicin patch has small, mainly uncontrolled CIPN studies suggesting pain relief. It is a clinician-applied treatment, not equivalent to a homemade chili cream, and it can cause considerable local discomfort. Pain improvement alone does not prove disease modification.

The useful options are not all in a bottle

The 2024 STOP trial randomized 158 people receiving oxaliplatin or vinca alkaloids to sensorimotor training, whole-body vibration or usual care. Neuropathy incidence was lower in the training groups among those assessed. There were missing assessments, and the result does not establish benefit for every chemotherapy regimen or longstanding neuropathy. Still, it is a good reason to discuss supervised balance and neuromuscular rehabilitation.

A small randomized acupuncture trial found symptom improvement compared with usual care, while sham acupuncture also improved some symptoms. That makes the size and specificity of the effect less certain. A time-limited trial with a qualified practitioner can be discussed, including cost, infection risk and blood counts.

Cooling and compression trials during taxane infusions have also shown encouraging prevention findings. These are treatment-center protocols, not instructions to ice numb feet at home. Ask your infusion team whether an appropriate protocol is available; cold injury and circulation problems matter.

So what would I want the conversation to include?

The 2020 ASCO guideline recommended no drug or supplement for CIPN prevention. For established painful CIPN, duloxetine had the strongest supporting drug evidence, with limited benefit. That guideline predates several studies above; newer positive trials deserve evaluation without being mistaken for an updated recommendation.

I would start with the cause, the chemotherapy exposure, reversible contributors and the thing neuropathy is stopping you from doing. Is the goal sleeping through the night? Walking safely? Using your hands? Then we can judge an intervention against something meaningful.

• Report new or worsening symptoms early, especially during treatment. Dose or schedule decisions belong with your oncology team.
• Ask about rehabilitation, balance, footwear and fall prevention alongside pain treatment.
• Bring all supplement labels. More ingredients do not necessarily mean more benefit.
• If an approach is reasonable for your situation, agree on what to measure, when to reassess and when to stop.
• Consider a clinical trial. NCI lists a study of ALA, Tai Chi/Qi Gong and acupuncture in colorectal cancer survivors; a trial listing is a research opportunity, not evidence that the treatment works.

I don’t think limited evidence should automatically end a conversation. It should make the conversation more specific. Which neuropathy, which outcome, how much benefit and what risk? That is the missing script I want us to write.

Educational evidence review, not individualized medical advice. “Natural cures” is a common search phrase, not a conclusion supported by these trials. Do not start supplements or change cancer treatment without discussing your circumstances with your care team. Sources are linked throughout; evidence checked October 2, 2026.

How we weigh evidence → · Get new essays →